Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma.
Biomarker and diagnostic research for pancreatic endocrine carcinoma has been reported in the published literature.
7 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 5 PHASE2, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05247905](https://clinicaltrials.gov/study/NCT05247905) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 1:11 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial |
PHASE2 |
Alliance for Clinical Trials in Oncology |
UNKNOWN |
[NCT01824875](https://clinicaltrials.gov/study/NCT01824875) | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | PHASE2 | ECOG-ACRIN Cancer Research Group | UNKNOWN |
[NCT00830557](https://clinicaltrials.gov/study/NCT00830557) | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | — | Mayo Clinic | RECRUITING |
[NCT02595424](https://clinicaltrials.gov/study/NCT02595424) | Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | PHASE2 | ECOG-ACRIN Cancer Research Group | ACTIVE_NOT_RECRUITING |
[NCT05988918](https://clinicaltrials.gov/study/NCT05988918) | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | PHASE2 | University of Michigan Rogel Cancer Center | ACTIVE_NOT_RECRUITING |
140 publications have been identified in PubMed for pancreatic endocrine carcinoma. Research spans Case Report / Case Series (29%), Basic Science / Preclinical (22%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 40 | 29% |
Laboratory research | 31 | 22% |
Research summaries | 25 | 18% |
Clinical study results | 17 | 12% |
Disease patterns and progression | 14 | 10% |
Testing and diagnosis research | 10 | 7% |
New treatment approaches | 2 | 1% |
Other research | 1 | 1% |
Oelschlägel L (2026). [PMID: 42197338](https://pubmed.ncbi.nlm.nih.gov/42197338/). *Microorganisms*. [Epidemiology / Natural History]
Okamoto K (2026). [PMID: 41866411](https://pubmed.ncbi.nlm.nih.gov/41866411/). *Journal of gastroenterology*. [Clinical Trial Publication]
Tomofuji S (2026). [PMID: 42189218](https://pubmed.ncbi.nlm.nih.gov/42189218/). *Acta Diabetol*. [Diagnostic / Biomarker]
Ogbu C (2026). [PMID: 41217437](https://pubmed.ncbi.nlm.nih.gov/41217437/). *Pancreas*. [Epidemiology / Natural History]
Alkatheeri M (2026). [PMID: 41852046](https://pubmed.ncbi.nlm.nih.gov/41852046/). *Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes*. [Diagnostic / Biomarker]
Gaujoux S (2026). [PMID: 41862416](https://pubmed.ncbi.nlm.nih.gov/41862416/). *World J Surg*. [Epidemiology / Natural History]
Sato S (2026). [PMID: 41760078](https://pubmed.ncbi.nlm.nih.gov/41760078/). *Medicine*. [Case Report / Case Series]
Ito F (2026). [PMID: 41541047](https://pubmed.ncbi.nlm.nih.gov/41541047/). *Clinical case reports*. [Case Report / Case Series]
Mastoraki A (2026). [PMID: 41868867](https://pubmed.ncbi.nlm.nih.gov/41868867/). *Annals of gastroenterology*. [Review / Meta-Analysis]
Kozlova N (2026). [PMID: 42045570](https://pubmed.ncbi.nlm.nih.gov/42045570/). *Nat Cell Biol*. [Basic Science / Preclinical]
AI-curated news mentioning pancreatic endocrine carcinoma
Updated Feb 15, 2026
A new study published in PubMed discusses endocrine carcinoma with an amphicrine carcinoma component located at the esophagogastric junction. This research adds to the understanding of rare cancer types and their characteristics.